2-Chloro-4-fluoro-5-[6-methoxy-7-(2-methoxy-ethoxy)-cinnolin-4-ylamino]-phenol

ID: ALA150826

Chembl Id: CHEMBL150826

PubChem CID: 6326407

Max Phase: Preclinical

Molecular Formula: C18H17ClFN3O4

Molecular Weight: 393.80

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  COCCOc1cc2nncc(Nc3cc(O)c(Cl)cc3F)c2cc1OC

Standard InChI:  InChI=1S/C18H17ClFN3O4/c1-25-3-4-27-18-8-13-10(5-17(18)26-2)15(9-21-23-13)22-14-7-16(24)11(19)6-12(14)20/h5-9,24H,3-4H2,1-2H3,(H,22,23)

Standard InChI Key:  JDPAKZCGVWMFFH-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA150826

   4-Anilinocinnoline deriv. 18

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 393.80

Molecular Weight (Monoisotopic): 393.0892

AlogP: 3.91

#Rotatable Bonds: 7

Polar Surface Area: 85.73

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 7.81

CX Basic pKa: 6.20

CX LogP: 2.55

CX LogD: 2.50

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.59

Np Likeness Score: -1.10

References

1. Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-van der Brempt C..  (1999)  Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.,  42  (26): [PMID:10639280] [10.1021/jm990345w]

2. Yu H, Wang Z, Zhang L, Zhang J, Huang Q..  (2007)  Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.,  17  (8): [PMID:17306530] [10.1016/j.bmcl.2007.01.089]

3. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data